NCT06537193Recruiting
Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment
A Prospective Multicenter Study for the Intra-Individual Comparison of Abbreviated MRI Using Gadoxetic Acid and Dynamic CT for Surveillance of Recurrent HCC After Curative Treatment
Source: ClinicalTrials.gov · Last updated 10 Mar 2026
Brief summary (registry, in English)
Hepatocellular carcinoma (HCC) often has a poor prognosis after curative treatment due to frequent recurrence. Post-surgery, 60-70% of HCC patients experience recurrence, rising to 80% after ablation therapy. This is partly because underlying cirrhosis or chronic liver disease remains, increasing the risk of secondary HCC. The risk of recurrence varies over time, with a high risk in the first two years due to micro-metastasis. Later recurrences are usually new primary cancers (de novo HCC). Therefore, regular imaging tests, such as computed tomography (CT) or magnetic resonance imaging (MRI) every three months in the first two years, are necessary for early detection, but guidelines for post-two-year screenings are unclear. Currently, for patients recurrence-free for two years, contrast-enhanced liver CT or MRI is performed every 3-6 months as a secondary screening test. However, repeated use of CT raises concerns about radiation exposure and iodine-based contrast agents can lead to side effects and kidney issues. MRI with hepatocyte-specific agents like gadoxetic acid (Primovist) is effective but costly and time-consuming, with potential side effects from repeated gadolinium exposure. Therefore, there is a need for a validated secondary screening method that is both effective and reduces patient risk. Abbreviated contrast-enhanced MRI, using only essential sequences, has shown promise in retrospective studies for detecting HCC. However, these studies have limitations, such as potential bias and lack of data on repeated screenings. There is limited research on secondary screening post-curative treatment for HCC. This study aims to prospectively evaluate the use of abbreviated contrast-enhanced MRI with Primovist as a secondary screening method for detecting secondary HCC in patients who have been recurrence-free for more than two years.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 455 (estimated)
- First submitted
- 30 Jul 2024
- Start date
- 12 Dec 2024
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- Asan Medical Center
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06537193
What you commit to
- Study type: Interventional
- Planned participants: 455
- From 12 Dec 2024 to the primary completion date, 31 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous history of severe allergic reaction to iodine contrast medium
Other illness
- Active or suspected cancer, or a history of malignancy where the risk of recurrence is equal or higher than 20% within 2 years.
- Patient not eligible for applying LI-RADS criteria, such as Budd-Chiari Syndrome
- Precautions for MRI (cardiac pacemaker, severe claustrophobia that may interfere with protocol compliance).
- Any other condition which, in the opinion of the Investigator, would make the patient unsuitable for enrollment or could interfere with completing the study.
Other
- Significant medical comorbidities in which survival is predicted to be less than 3 years
- Estimated glomerular filtration rate \< 30 mL/min/1.73m²
- Child-Pugh class C
Who the study is looking for
- Patients with more than two years without recurrence after curative treatment (surgery or local ablation) for HCC
- Patients with no history of systemic treatment, radiation therapy, or trans-arterial chemoembolization for HCC
- Older than 20 years of age
- Eastern Cooperative Oncology Group performance status of 0-2
- Patient is able to comply with scheduled visits, evaluation plans, and other study procedures
- Patient is willing to provide written informed consent
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Asan Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.